U.S. PHARMACOPEIA

Search USP29  
Sumatriptan
Click to View Image
C14H21N3O2S 295.40

1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-.
3-[2-(Dimethylamino)ethyl]-N-methy-1H-indole-5-methanesulfonamide [103628-46-2].
» Sumatriptan contains not less than 98.0 percent and not more than 102.0 percent of C14H21N3O2S, calculated on the anhydrous and solvent-free basis.
Packaging and storage— Preserve in tight, light resistant containers. Protect from freezing, and store below 30º.
USP Reference standards 11 USP Sumatriptan RS. USP Sumatriptan Succinate RS. USP Sumatriptan Succinate Related Compound A RS. USP Sumatriptan Succinate Related Compound C RS. USP Sumatriptan Succinate Related Impurities RS.
Identification—
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Water, Method I 921: not more than 1.0%.
Limit of sumatriptan related compound A—
10 M Ammonium acetate solution— Dissolve 77.1 g of ammonium acetate in 100 mL of water.
Mobile phase— Prepare a filtered and degassed mixture of methanol and 10 M Ammonium acetate solution (9:1). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard solution— Dissolve an accurately weighed quantity of USP Sumatriptan Succinate Related Compound A RS in Mobile phase, and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of about 0.00625 mg per mL.
Test solution— Transfer about 100 mg of Sumatriptan, accurately weighed, to a 50-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 282-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L3. The flow rate is about 2.0 mL per minute. Chromatograph the Standard solution, and record the peak responses as directed for Procedure: the relative standard deviation for replicate injections is not more than 5%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the percentage of sumatriptan related compound A in the portion of Sumatriptan taken by the formula:
100(495.7/613.8)(CS /CU)(rU /rS),
in which 495.7 and 613.8 are the molecular weights of sumatriptan related compound A and sumatriptan succinate related compound A, respectively; CS is the concentration, in mg per mL, of USP Sumatriptan Succinate Related Compound A RS in the Standard solution; CU is the concentration, in mg per mL, of Sumatriptan in the Test solution; and rU and rS are the peak responses for sumatriptan related compound A obtained from the Test solution and the Standard solution, respectively: not more than 0.6% is found.
Related compounds—
Diluent and System suitability solution— Proceed as directed in the Assay.
Buffer solution— Dissolve about 1.7 mL of dibutylamine, about 0.6 mL of phosphoric acid, and about 3.9 g of monobasic sodium phosphate dihydrate in water. Adjust with a solution of 50 % (w/v) sodium hydroxide to a pH of about 7.5, dilute with water to 1000 mL, and mix.
Mobile phase— Prepare a filtered and degassed mixture of Buffer solution and acetonitrile (3:1). Make adjustments if necessary (see System Suitability under Chromatography 621).
Identification solution— Prepare a solution of USP Sumatriptan Succinate Related Impurities RS in Mobile phase having a concentration of about 3 mg per mL.
Test solution— Dissolve an accurately weighed quantity of Sumatriptan in Diluent to obtain a solution having a concentration of about 2 mg per mL.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 282-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 1.5 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.9 for sumatriptan succinate related compound C and 1.0 for sumatriptan; the resolution, R, between sumatriptan succinate related compound C and sumatriptan is not less than 1.5. Chromatograph the Identification solution, and record the peak responses as directed for Procedure: identify the peaks according to Table 1.
Table 1
Compound Name Relative Retention Time Limit (%)
[3-[2-(Dimethylamino N-oxide)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide about 0.3 0.2
[3-[2-(Methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide about 0.6 0.5
Sumatriptan succinate related compound C about 0.9 0.5
Sumatriptan 1.0
[3-[2-(Aminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide about 0.4 0.1
Unknown impurities 0.1
Total 1.5
[NOTE—The calculation of total impurities includes the amount of sumatriptan related compound A, determined in the test for Limit of sumatriptan related compound A.]
Procedure— Inject a volume (about 10 µL) of the Test solution into the chromatograph, record the chromatogram, and measure all of the peak responses. Calculate the percentage of each impurity in the portion of Sumatriptan taken by the formula:
100(ri / rs),
in which ri is the peak response for each impurity, and rs is the sum of the responses of all the peaks: meets the requirements given in Table 1.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay—
Diluent— Dissolve 3.9 g of monobasic sodium phosphate dihydrate in water. Adjust with a solution of 50 % (w/v) sodium hydroxide to a pH of about 6.5, and dilute with water to 1000 mL. Mix 750 mL of this solution with 250 mL of acetonitrile.
Buffer solution— Dissolve about 1.7 mL of dibutylamine, about 0.6 mL of phosphoric acid, and about 3.9 g of monobasic sodium phosphate dihydrate in water. Adjust with a solution of 50 % (w/v) sodium hydroxide to a pH of about 6.5, dilute with water to 1000 mL, and mix.
Mobile phase— Prepare a filtered and degassed mixture of Buffer solution and acetonitrile (3:1). Make adjustments if necessary (see System Suitability under Chromatography 621).
System suitability solution— Dissolve accurately weighed quantities of USP Sumatriptan Succinate RS and USP Sumatriptan Succinate Related Compound C RS in Diluent to obtain a solution having known concentrations of about 0.28 mg per mL and 0.14 mg per mL, respectively.
Standard preparation— Dissolve an accurately weighed quantity of USP Sumatriptan Succinate RS in Diluent to obtain a solution having a known concentration of about 0.14 mg per mL.
Assay preparation— Transfer about 10 mg of Sumatriptan, accurately weighed, to a 100-mL volumetric flask. Dissolve in and dilute with Diluent to volume, and mix.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 282-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 1.5 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.9 for sumatriptan succinate related compound C and 1.0 for sumatriptan; and the resolution, R, between sumatriptan succinate related compound C and sumatriptan is not less than 1.5. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the relative standard deviation for replicate injections is not more than 1.5%.
Procedure— Separately inject equal volumes (about 10 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the amount, in mg, of C14H21N3O2S in the portion of Sumatriptan taken by the formula:
(295.4/413.5)100C(rU / rS),
in which 295.4 and 413.5 are the molecular weights of sumatriptan and sumatriptan succinate, respectively; C is the concentration, in mg per mL, of USP Sumatriptan Succinate RS in the Standard preparation; and rU and rS are the peak responses for sumatriptan obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Ravi Ravichandran, Ph.D., Senior Scientist
Expert Committee : (MDPP05) Monograph Development-Psychiatrics and Psychoactives
USP29–NF24 Page 2046
Pharmacopeial Forum : Volume No. 30(1) Page 184
Phone Number : 1-301-816-8330